肝细胞癌局部治疗后疗效评估:肝胆特异性对比剂与细胞外对比剂MRI的比较
本文综述对比增强MRI在肝细胞癌局部治疗后疗效评估中的应用,比较细胞外对比剂(ECA)与肝胆特异性对比剂(HBA)的影像表现。基于LI-RADS治疗反应算法(TRA),HBA可获取肝胆期(HBP)图像,提高高危患者小病灶检出敏感度,但尚未纳入TRA标准;已有少数研究评估HBP辅助征象调整LI-RADS分类,可在不显著损失特异度前提下提高诊断敏感度。
要点
- LI-RADS TRA当前基于ECA,HBA尚未正式纳入但临床使用日益增多。
- HBA可获取HBP,提高<2 cm病灶检出敏感度,有助于疗效评估。
- HBP辅助征象可调整LI-RADS分类,提高敏感度且不显著损失特异度。
关键影像表现/征象
- HBA可获取肝胆期(HBP)图像,提高高危患者病灶检出敏感度,尤其<2 cm的病灶。
- HBP相关辅助征象可导致LI-RADS分类调整,使诊断更敏感和明确。
- 与ECA-based LI-RADS TRA评估相比,HBP辅助征象调整分类不显著损失特异度。
诊断标准与关键数值
- LI-RADS TRA允许使用常规钆基细胞外对比剂(ECA)进行肿瘤反应评估。
- HBA尚未纳入TRA标准,但HBP辅助征象可用于分类调整。
临床应用与阅片要点
- 日常阅片可关注HBP图像及辅助征象,辅助LI-RADS TRA分类调整。
- 使用HBA评估疗效时需注意HBP辅助征象的陷阱,避免过度诊断。
局限性
- HBA尚未纳入LI-RADS TRA标准,相关证据来自少数已发表研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Cross-sectional imaging with contrast-enhanced magnetic resonance imaging (MRI) is routinely performed in patients with hepatocellular carcinoma (HCC) to assess tumor response to locoregional therapy (LRT). Current response assessment algorithms, such as the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (TRA), allow assessment using conventional gadolinium-based extracellular contrast agents (ECA) for accurate tumor response assessment following LRT. MRI with hepatobiliary agents (HBA) allows an acquisition of hepatobiliary phase (HBP), which is proven to increase sensitivity for detection of observations in at-risk patients, particularly for findings < 2 cm. The use of HBA is not yet incorporated into the TRA; however, it is increasingly used in clinical practice. Few published studies have evaluated the performance of LI-RADS TRA by applying ancillary features related to HBP that has resulted in category adjustment, enabling more sensitive and unequivocal diagnosis. This may help timely management of viable cases, without a significant loss of specificity in comparison with the ECA-based LI-RADS TRA assessment. In this review, we will describe and compare the imaging appearance of treated HCC on MRI using extracellular and hepatobiliary contrast agents and discuss emerging evidence and pitfalls in the assessment of tumor response following LRT with HBA.
引用
- Aslam A, Kamath A, Spieler B, et al. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY). 2021. PMID: 33856509. doi:10.1007/s00261-021-03076-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。